In restrictive cardiomyopathies with clear secondary factors, the primary cause should be treated first and will not be described here. For the treatment of restrictive cardiomyopathy itself, there is a lack of very effective treatment. Diuretic therapy is an important tool to relieve the symptoms of heart failure in patients. The appropriate use of diuretics can improve the quality of life and activity tolerance of patients, but the use of diuretic drugs requires attention to the following issues: 1. In patients with restrictive cardiomyopathy, small changes in left heart preload may cause large changes in blood pressure due to increased myocardial stiffness. A possible clinical situation is that the patient’s heart failure symptoms worsen when diuresis is inadequate; and the patient will experience a decrease in blood pressure after strengthening diuresis. The so-called ideal preload state is that which ensures perfusion of vital organs without causing heart failure symptoms, but may not exist in some patients with restrictive cardiomyopathy. In this case, it is recommended to ensure the blood pressure of the body circulation first, even if the patient has symptoms of heart failure, do not affect the blood pressure because of excessive diuresis. The consequences of excessive diuresis, besides affecting blood pressure and organ perfusion, may reflexively excite the sympathetic nerves and cause various malignant arrhythmias and even sudden death. 2, Diuretics are only a symptomatic treatment and cannot improve the long-term prognosis of patients. 3. Since patients with restrictive cardiomyopathy can have various malignant arrhythmias, electrolyte balance should be closely monitored when using diuretics. The role of B-one receptor blockers in the treatment of restrictive cardiomyopathy is not certain, despite their increasing use in other cardiomyopathies. The use of B-blockers may help to reduce the risk of malignant arrhythmias in this group of patients. Treatment with afterload control may be useful in some patients with restrictive cardiomyopathy who have mildly reduced ejection fraction or moderate or severe mitral regurgitation, but the role is not certain in patients who exhibit only restrictive diastolic dysfunction. Restrictive cardiomyopathy is a group of cardiomyopathies characterized by restrictive diastolic dysfunction. There is a lack of accepted diagnostic criteria, and a combination of clinical manifestations and imaging studies is required for diagnosis. It has been found that for some primary restrictive cardiomyopathies, the onset of the disease is associated with mutations in genes such as myosin. Restrictive cardiomyopathy has a poor prognosis and there is a lack of effective pharmacological treatment. In pediatric patients, early heart transplantation has the potential to improve the prognosis in this group of patients, given that sudden death can occur in the absence of overt heart failure symptoms.